Trial Profile

A Randomized, Controlled, Multi-site Study About Safety and Efficacy of Pirfenidone to Treat Grade 2 or Grade3 Radiation-induced Lung Injury

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 13 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pirfenidone (Primary) ; Glucocorticoids
Indications Lung injury; Radiation injuries
Focus Therapeutic Use
Sponsors Beijing Continent Pharmaceutical

Most Recent Events

02 May 2025 Status changed from discontinued to completed.
13 Jun 2022 Status changed from recruiting to discontinued.
08 Oct 2021 Planned End Date changed from 30 Apr 2021 to 30 Jun 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com